Phase I Clinical Trial Definition & Meaning | Health Care Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Phase I Clinical Trial

Health Care Term

Phase I clinical trial is the first step of testing new drugs or medical interventions in human subjects to evaluate the safety, tolerability, and pharmacological properties of the intervention. This trial usually involves a small group of healthy volunteers or individuals with the target disease who have not undergone any treatment before. The primary goal of a phase I trial is to determine the highest safe dose of the new intervention and assess its toxicity and adverse effects.

During a phase I clinical trial, researchers collect data on various parameters such as the drug*s pharmacodynamics, pharmacokinetics, and metabolic profile. They also evaluate the drug*s efficacy, including its ability to target and interact with the intended biological targets. The trial is designed to identify the optimal dosage and administration regimen, as well as the drug*s safety and tolerability profile.

Phase I clinical trials are essential in the health care industry as they provide critical information on the safety and feasibility of a new intervention. The trial*s results can help researchers and regulatory agencies decide whether to proceed with further clinical testing in Phase II and III trials or discontinue development due to safety concerns. In addition, phase I trials are instrumental in informing physicians and patients about the potential risks and benefits of new interventions, aiding in the informed decision-making process. Overall, phase I clinical trials advance the understanding of the biology and the development of better treatments for patients.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P